Letermovir vs. high-dose valacyclovir for cytomegalovirus prophylaxis following haploidentical or mismatched unrelated donor allogeneic hematopoietic cell transplantation receiving post-transplant cyclophosphamide.
Letermovir
cytomegalovirus
haploidentical
post-transplant cyclophosphamide
prophylaxis
valacyclovir
Journal
Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
pubmed:
22
2
2022
medline:
19
8
2022
entrez:
21
2
2022
Statut:
ppublish
Résumé
Patients undergoing haploidentical or mismatched unrelated donor (haplo/MMUD) allogeneic hematopoietic cell transplantation (alloHCT) receiving post-transplant cyclophosphamide (PTCy) are at high risk of cytomegalovirus (CMV) infection. Experience with letermovir (LET) in this population is limited. This single center retrospective cohort study compared CMV and transplant outcomes between LET and a historical control with high-dose valacyclovir (HDV) prophylaxis in adults undergoing haplo/MMUD alloHCT. Thirty-eight CMV seropositive patients were included, 19 in each arm. LET reduced the incidence of CMV infection (5% vs. 53%, RR 0.01, 95% CI 0.014-0.71,
Identifiants
pubmed: 35188052
doi: 10.1080/10428194.2022.2042686
doi:
Substances chimiques
Acetates
0
Quinazolines
0
letermovir
1H09Y5WO1F
Cyclophosphamide
8N3DW7272P
Valacyclovir
MZ1IW7Q79D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM